These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 19752302)

  • 21. Analysis of the treatment of neuromyelitis optica.
    Torres J; Pruitt A; Balcer L; Galetta S; Markowitz C; Dahodwala N
    J Neurol Sci; 2015 Apr; 351(1-2):31-35. PubMed ID: 25727350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Wang Y; Ma J; Chang H; Zhang X; Yin L
    Mult Scler Relat Disord; 2021 Oct; 55():103181. PubMed ID: 34365314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
    Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
    Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical spectrum of CNS aquaporin-4 autoimmunity.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Neurology; 2012 Apr; 78(15):1179-85. PubMed ID: 22459676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
    Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
    Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of IgG-NMO autoantibodies on S100Beta protein and disability in relapsing neuromyelitis optica.
    Robinson-Agramonte MA; Gonçalves CA; Portela LV; Saiz-Hinarejos A; Oses JP; Motta LS; Muller AP; Marquez Gonzalez ME; Souza DO
    Neuroimmunomodulation; 2010; 17(3):177-9. PubMed ID: 20134196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
    Altintas A; Karabudak R; Balci BP; Terzi M; Soysal A; Saip S; Tuncer Kurne A; Uygunoglu U; Nalbantoglu M; Gozubatik Celik G; Isik N; Celik Y; Gokcay F; Duman T; Boz C; Yucesan C; Mangan MS; Celebisoy N; Diker S; Colpak Isikay I; Kansu T; Siva A
    Neurologist; 2015 Oct; 20(4):61-6. PubMed ID: 26468870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.
    Ayzenberg I; Kleiter I; Schröder A; Hellwig K; Chan A; Yamamura T; Gold R
    JAMA Neurol; 2013 Mar; 70(3):394-7. PubMed ID: 23358868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate.
    Yang Y; Chen L; Wu L; Yao J; Wang N; Su X; Li D; Han L; Wu W; Huang D; Jiang T; Wang Z
    Neurol Ther; 2022 Mar; 11(1):137-149. PubMed ID: 34797551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics of disabling attacks at onset in patients with neuromyelitis optica spectrum disorder.
    Seok JM; Cho EB; Lee HL; Cho HJ; Min JH; Lee KH; Kim BJ
    J Neurol Sci; 2016 Sep; 368():209-13. PubMed ID: 27538635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuromyelitis optica in Portugal (NEMIPORT) - A multicentre study.
    Domingos J; Isidoro L; Figueiredo R; Brum M; Capela C; Barros P; Santos E; Macário Mdo C; Pinto Marques J; Pedrosa R; Vale J; Sá MJ
    Clin Neurol Neurosurg; 2015 Jul; 134():79-84. PubMed ID: 25965287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients.
    Sahraian MA; Moinfar Z; Khorramnia S; Ebrahim MM
    Eur J Neurol; 2010 Jun; 17(6):794-9. PubMed ID: 20100229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Arch Neurol; 2011 Nov; 68(11):1412-20. PubMed ID: 21747007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
    Jarius S; Aboul-Enein F; Waters P; Kuenz B; Hauser A; Berger T; Lang W; Reindl M; Vincent A; Kristoferitsch W
    Brain; 2008 Nov; 131(Pt 11):3072-80. PubMed ID: 18945724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
    Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I;
    J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.